Dr. Emad Elquza, MD

Dr. Elquza practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Elquza's NPI, 1437355534, was assigned on June 25, 2007. Dr. Elquza graduated from The Flinders University of South Australia School of Medicine in 2004. Dr. Elquza holds California license C167835.

Dr. Elquza's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Elquza's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. The medical group on file is UCI Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Elquza practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Elquza's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Elquza is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Elquza's licenses on file in 2 states: California and Arizona.

Dmand AI lists chronic anemia, colorectal cancer and lung cancer among the conditions Dr. Elquza treats.

CMS data shows 12 Medicare services from Dr. Elquza across 1 procedure code in 2024, for 28 Medicare patients. Medicare paid $1,856 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 28 Medicare patients who saw Dr. Elquza in 2024. The largest group is 75 to 84, with 14 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 43% are also on Medicaid. Their average risk score is 3.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Elquza's median patient age at 64, with 55% women.

In 2024, Dr. Elquza wrote 106 Medicare Part D claims for 16 patients. 89% of them were for generic drugs. CMS names the drug for 33 of them, across 3 drugs with 11 or more claims each, at $240 in total drug cost. In 2020, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Elquza for performance year 2024, reported through an alternative payment model (APM). Dr. Elquza accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Elquza as offering telehealth.

Dmand AI links 32 papers to Dr. Elquza, published from 2015 to 2021. 2015 was the busiest year, with 6. The most frequent topics are Arizona, Colorectal Neoplasms and Adenocarcinoma. Dr. Elquza has published most often in Am J Surg. Dr. Elquza's most frequent co-authors are Valentine Nfongen Nfonsam, MD, Aaron James Scott, MD and Viraj Pandit, MD.

Dmand AI links Dr. Elquza to 7 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Pancreatic Neoplasms, Pancreatic Diseases and Esophageal Neoplasms. SWOG Cancer Research Network sponsors the most, 2.

CMS Open Payments shows 16 general payments to Dr. Elquza from 10 drug and device companies from 2016 to 2019. Food and beverage make up the largest share, 94% of the total. Amgen Inc. paid the most, $146.

Dr. Elquza graduated from The Flinders University of South Australia School of Medicine in 2004.

Dr. Elquza is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.